Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Chem Commun (Camb) ; 54(98): 13841-13844, 2018 Dec 06.
Article in English | MEDLINE | ID: mdl-30468218

ABSTRACT

A novel, simple, one-step and one-tube detection method was developed for ultrasensitive detection of polynucleotide kinase (PNK) activity on the basis of dual enzyme-synergistic signal amplification. This method was also demonstrated to work well for PNK inhibitor screening and endogenous PNK detection in cell lysates at a single-cell level.


Subject(s)
Enzyme Assays/methods , Polynucleotide 5'-Hydroxyl-Kinase/analysis , Drug Evaluation, Preclinical/economics , Drug Evaluation, Preclinical/methods , Enzyme Assays/economics , HeLa Cells , Humans , Polynucleotide 5'-Hydroxyl-Kinase/antagonists & inhibitors , Protein Kinase Inhibitors/pharmacology , Spectrometry, Fluorescence/methods , Temperature
2.
Enzyme Microb Technol ; 116: 72-76, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29887020

ABSTRACT

A novel kinetic method was developed for the quantitation of α-ketoglutaric acid (AKG) in cardioplegic solution and athletic supplements. The assay relied on an enzymatic transamination of AKG and d-4-hydroxyphenylglycine to form 4-hydroxybenzoylformic acid and l-glutamic acid using d-phenylglycine aminotransferase. Since 4-hydroxybenzoylformic acid absorbed UV strongly at 334 nm, the initial rate of the reaction was determined by the increasing absorbance at this wavelength without the need for colorimetric probes or coupling reactions, and this information was used for the construction of a standard curve against AKG concentration. The method showed good linearity (r2 = 0.9994) over an AKG concentration range of 20-160 µM. The limits of detection and quantitation were 4.09 and 13.62 µM respectively. It was simple, inexpensive, accurate and precise, as well as repeatable, and was not interfered with by excipients in the samples. Regarding the environmental friendliness, the method was free from the use of organic solvents or hazardous reagents and required no chemical pre-treatment of samples. The proposed method gave assay results tested in real samples in agreement with the HPLC method and commercial assay kits, therefore being suitable for routine analysis of AKG in quality control laboratories.


Subject(s)
Cardioplegic Solutions/analysis , Dietary Supplements/analysis , Enzyme Assays/methods , Ketoglutaric Acids/analysis , Transaminases/chemistry , Enzyme Assays/economics , Kinetics
3.
Biosci Rep ; 36(3)2016 06.
Article in English | MEDLINE | ID: mdl-27013337

ABSTRACT

Diacylglycerol lipase α (DAGLα) hydrolyses DAG to generate the principal endocannabinoid (eCB) 2-arachidonoylglycerol (2-AG) in the central nervous system. DAGLα dependent cannabinoid (CB) signalling has been implicated in numerous processes including axonal growth and guidance, adult neurogenesis and retrograde signalling at the synapse. Recent studies have implicated DAGLα as an emerging drug target for several conditions including pain and obesity. Activity assays are critical to the drug discovery process; however, measurement of diacylglycerol lipase (DAGL) activity using its native substrate generally involves low-throughput MS techniques. Some relatively high-throughput membrane based assays utilizing surrogate substrates have been reported, but these do not take into account the rate-limiting effects often associated with the ability of a drug to cross the cell membrane. In the present study, we report the development of a live cell assay to measure DAGLα activity. Two previously reported DAGLα surrogate substrates, p-nitrophenyl butyrate (PNPB) and 6,8-difluoro-4-methylumbelliferyl octanoate (DiFMUO), were evaluated for their ability to detect DAGLα activity in live cell assays using a human cell line stably expressing the human DAGLα transgene. Following optimization, the small molecule chromogenic substrate PNPB proved to be superior by providing lower background activity along with a larger signal window between transfected and parental cells when compared with the fluorogenic substrate DiFMUO. The assay was further validated using established DAGL inhibitors. In summary, the live cell DAGLα assay reported here offers an economical and convenient format to screen for novel inhibitors as part of drug discovery programmes and compliments previously reported high-throughput membrane based DAGL assays.


Subject(s)
Enzyme Assays/methods , Lipoprotein Lipase/metabolism , Butyrates/metabolism , Cell Line , Cell Survival , Drug Evaluation, Preclinical/economics , Drug Evaluation, Preclinical/methods , Enzyme Assays/economics , Enzyme Inhibitors/pharmacology , Halogenation , Humans , Hymecromone/analogs & derivatives , Hymecromone/metabolism , Lipoprotein Lipase/antagonists & inhibitors
4.
Anal Chem ; 87(2): 1257-65, 2015 Jan 20.
Article in English | MEDLINE | ID: mdl-25521387

ABSTRACT

We report a rapid colorimetric assay to detect protein phosphatase (PP) activity based on the controlled assembly and disassembly of gold nanoparticles (AuNPs) via Zn(II)-specific coordination in the presence of His6-tagged phosphopeptides. Among divalent metal ions including Ni(II), Cu(II), Co(II), Mg(II), Mn(II), and Zn(II), only Zn(II) triggered a strong association between phosphopeptides with hexahistidine at a single end and nitrilotriacetic acid (NTA)-modified AuNPs (21.3 nm in core diameter), leading to the self-assembly of AuNPs and consequently changes in color of the AuNP solution. In contrast, unphosphorylated peptides and His6-deficient phosphopeptides did not change the color of the AuNP solution. As a result, protein phosphatase 1 (PP1) activity and its inhibition were easily quantified with high sensitivity by determining the extinction ratio (E520/E700) of colloidal AuNPs. Most importantly, this method was capable of detecting protein phosphatase 2A (PP2A) activity in immunoprecipitated plant extracts. Because PPs play pivotal roles in mediating diverse signal transduction pathways as primary effectors of protein dephosphorylation, we anticipate that our method will be applied as a rapid format method to analyze the activities of various PPs and their inhibition.


Subject(s)
Arabidopsis/enzymology , Enzyme Assays/methods , Phosphopeptides/metabolism , Phosphoprotein Phosphatases/metabolism , Amino Acid Sequence , Arabidopsis/metabolism , Colorimetry/economics , Colorimetry/methods , Enzyme Assays/economics , Gold/chemistry , Histidine/chemistry , Histidine/metabolism , Metal Nanoparticles/chemistry , Oligopeptides/chemistry , Oligopeptides/metabolism , Phosphopeptides/chemistry
5.
Anal Biochem ; 447: 146-55, 2014 Feb 15.
Article in English | MEDLINE | ID: mdl-24299989

ABSTRACT

Glycosyltransferases catalyze transfer of sugar moieties from activated donor molecules to specific acceptor molecules, forming glycosidic bonds. Identification of selective modulators of glycosyltransferases is important both to provide new tools for investigating pathophysiological roles of glycosylation reactions in cells and tissues, and as new leads in drug discovery. Here we describe a universal enzyme-coupled fluorescence assay for glycosyltransferases, based on quantification of nucleotides produced in the glycosyl transfer reaction. GDP, UDP, and CMP are phosphorylated with nucleotide kinase in the presence of excess ATP, generating ADP. Via coupled enzyme reactions involving ADP-hexokinase, glucose-6-phosphate dehydrogenase, and diaphorase, the ADP is utilized for conversion of resazurin to resorufin, which is determined by fluorescence measurement. The method was validated by comparison with an HPLC method, and employed to screen the LOPAC1280 library for inhibitors in a 384-well plate format. The assay performed well, with a Z'-factor of 0.80. We identified 12 hits for human galactosyltransferase B4GALT1 after elimination of false positives that inhibited the enzyme-coupled assay system. The assay components are all commercially available and the reagent cost is only 2 to 10 US cents per well. This method is suitable for low-cost, high-throughput assay of various glycosyltransferases and screening of glycosyltransferase modulators.


Subject(s)
Enzyme Assays/methods , Fluorescence , Glycosyltransferases/metabolism , Luminescent Measurements/methods , Cost-Benefit Analysis , Drug Evaluation, Preclinical , Enzyme Assays/economics , Enzyme Inhibitors/pharmacology , Glycosyltransferases/antagonists & inhibitors , Humans , Nucleotides/metabolism , Reproducibility of Results , Small Molecule Libraries/pharmacology
6.
Anal Chem ; 84(13): 5794-800, 2012 Jul 03.
Article in English | MEDLINE | ID: mdl-22656268

ABSTRACT

Droplet-based microfluidics is an attractive platform for screening and optimizing chemical reactions. Using this approach, it is possible to reliably manipulate nanoliter volume samples and perform operations such as reagent addition with high precision, automation, and throughput. Most studies using droplet microfluidics have relied on optical techniques to detect the reaction; however, this requires engineering color or fluorescence change into the reaction being studied. In this work, we couple electrospray ionization mass spectrometry (ESI-MS) to nanoliter scale segmented flow reactions to enable direct (label-free) analysis of reaction products. The system is applied to a screen of inhibitors for cathepsin B. In this approach, solutions of test compounds (including three known inhibitors) are arranged as an array of nanoliter droplets in a tube segmented by perfluorodecalin. The samples are pumped through a series of tees to add enzyme, substrate (peptides), and quenchant. The resulting reaction mixtures are then infused into a metal-coated, fused silica ESI emitter for MS analysis. The system has potential for high-throughput as reagent addition steps are performed at 0.7 s per sample and ESI-MS at up to 1.2 s per sample. Carryover is inconsequential in the ESI emitter and between 2 and 9% per reagent addition depending on the tee utilized. The assay was reliable with a Z-factor of ~0.8. The method required 0.8 pmol of test compound, 1.6 pmol of substrate, and 5 fmol of enzyme per reaction. Segmented flow ESI-MS allows direct, label free screening of reactions at good throughput and ultralow sample consumption.


Subject(s)
Cathepsin B/antagonists & inhibitors , Enzyme Assays/instrumentation , Enzyme Inhibitors/pharmacology , Microfluidic Analytical Techniques/instrumentation , Spectrometry, Mass, Electrospray Ionization , Dimethylpolysiloxanes/chemistry , Drug Evaluation, Preclinical/economics , Drug Evaluation, Preclinical/instrumentation , Enzyme Assays/economics , Equipment Design , Humans , Microfluidic Analytical Techniques/economics
7.
Methods Mol Biol ; 644: 91-116, 2010.
Article in English | MEDLINE | ID: mdl-20645167

ABSTRACT

The need for the development of selective agents, which only inhibit the mainly "harmful" cyclooxygenase-2 (COX-2) while leaving physiological COX-1 mostly unaffected, still remains, especially after the recent issues related to cardiovascular toxicity caused by some COX-2 selective agents. Thus there is still a demand for sensitive and rapid methods to assay for COX-2 selective agents. Among several in vitro testing systems the whole blood assay (WBA) is a well-known method to examine non-steroidal anti-inflammatory drugs (NSAIDs) in view of their potency to inhibit COX activity. This assay has some major advantages over enzyme-based or isolated cell assays. Emergence of artifacts due to cell separation steps is kept to a minimum and substances, even in disproportional high concentrations, can be examined outside the body in a physiological environment resembling most closely the in vivo conditions in living humans, i.e., 37 degrees C, homeostasis, presence of all blood compounds and cell-cell interactions remain intact. While COX-1 human whole blood assays are performed within less than 2 h, for established COX-2 assays one still has to allow for an overnight incubation step before gaining the desired plasma. The aim of the assay described in this chapter is to characterize an optimized human whole blood assay (hWBA). We present a simple, fast and reliable method to examine the capacity of NSAIDs at inhibiting COX-2 activity that can be applied for rapid and routine screening purposes.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/blood , Cyclooxygenase 1/blood , Cyclooxygenase 2/blood , Cyclooxygenase Inhibitors/blood , Drug Evaluation, Preclinical/methods , Enzyme Assays/methods , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Arachidonate 5-Lipoxygenase/metabolism , Blood/drug effects , Blood Platelets/drug effects , Blood Platelets/enzymology , Cyclooxygenase 1/metabolism , Cyclooxygenase 2/metabolism , Cyclooxygenase Inhibitors/pharmacology , Dinoprostone/blood , Dinoprostone/metabolism , Drug Evaluation, Preclinical/economics , Enzyme Assays/economics , Enzyme-Linked Immunosorbent Assay/methods , Granulocytes/drug effects , Granulocytes/enzymology , Humans , Leukotriene B4/metabolism , Lipopolysaccharides/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL